FDA Approves CALQUENCE® and Venetoclax as First Fixed-Duration, All-Oral Regimen for Frontline CLL
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting AstraZeneca’sCALQUENCE® in combination with venetoclax has been approved…
Seaport Therapeutics Shares Meta-Analysis Highlighting Trial Design Effects on Placebo Response in GAD
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials Seaport Therapeutics a clinical-stage therapeutics company advancing novel neuropsychiatric…
FDA Accepts Genentech’s NDA for Giredestrant in ESR1-Mutated Advanced Breast Cancer
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration…
Element Biosciences Unveils VITARI™ to Transform High-Throughput Sequencing
Element Biosciences Introduces VITARI™, Redefining What High-Throughput Sequencing Makes Possible Element Biosciences Inc. today announced VITARI, the first ever high-throughput benchtop sequencing system capable of delivering a high-quality whole genome at…
Phase 3 Data Support ENTYVIO® (vedolizumab) for Pediatric Moderate to Severe Ulcerative Colitis
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis Takeda today announced positive data from the pivotal…
Dock Health Deploys Workflow Productivity Platform at Mayo Clinic
Dock Health Introduces Its Productivity Platform at Mayo Clinic to Modernize Operational Workflows Dock Health today announced that its productivity platformhas been implemented at Mayo Clinic to automate and optimize operational workflows in its cardiovascular,…
NexEos Bio Secures FDA Green Light to Progress NTX-1024 into Phase II/III Clinical Development
NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis NexEos Bio Vision Health a clinical-stage biopharmaceutical company developing novel therapies…
Case Study Shows CyPath® Lung Reduces Diagnostic Burden in At-Risk Patients
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer bioAffinity Technologies, Inc. a biotechnology company advancing noninvasive diagnostics for…
Unified Women’s Healthcare Addresses Growing Demand for Menopause Care
Unified Women’s Healthcare Responds to Rising Demand for Menopause Care Unified Women’s Healthcare (Unified), in partnership with its OBGYN affiliates, is expanding access to perimenopause and menopause care nationwide through Unified for…
ImmunityBio Expands EU Access to ANKTIVA® with New Distribution Deal
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch ImmunityBio, Inc. a commercial-stage immunotherapy company, today announced a partnership with Accord…
BioTalent Canada Launches Workplace Harassment Prevention Training
BioTalent Canada Launches Training to Help Employers Prevent and Respond to Workplace Sexual Harassment BioTalent Canada is launching online training courses to empower managers and hiring leaders to confidently prevent…
bit.bio Expands Global Access to Human Cells with New Pricing and Hub
bit.bio Accelerates Global Access to Human Cells with New Pricing Model and Distribution Hub Following a record Q4 in sales volume and the successful closing of $50 million in new…